Denied Claims + Underpaid Claims + Forward Solutions
Medicare Advantage plans deny 17% of oncology claims initially — with $1.4-3.4 billion in wrongful denials industry-wide. We recover what's rightfully yours with AI-powered claims analysis and a 5-year lookback. 100% contingency-based — you pay nothing unless we recover money for you.
Schedule a Discovery CallThe Problem
Medicare Advantage plans deny oncology infusion claims at alarming rates. With 99% of MA enrollees requiring prior authorization for chemotherapy, the administrative burden is crushing practices while billions in legitimate claims go unrecovered.
The data is clear: 13-18% of MA denials are for services that meet Medicare coverage rules — wrongful denials that cost the oncology industry $1.4-3.4 billion annually.
Our Solution
Precision DX Group's three-phase approach prevents denials before they happen and recovers historical claims going back 5 years. Our AI platform validates ICD-10 codes against NCCN guidelines and automates the appeal process.
We operate on a performance-based model — you pay nothing until we recover your money.
AI-driven prior authorization, policy compliance checks, ICD-10 validation, and documentation verification before treatment.
Real-time charge capture, drug & coding validation, and site-of-service optimization to prevent claim errors.
AI-powered denial analysis, automated appeal generation, and historical A/R recovery with 5-year lookback.
What We Recover
IV chemotherapy administration, drug costs, and related services — $5,000 to $16,000+ per infusion.
Checkpoint inhibitors, CAR-T therapy, and other immunotherapy protocols with high denial rates.
78.9% of Part B drug spending is on biologics — prime targets for MA prior auth denials.
Hydration, anti-nausea, blood products, and supportive medications often bundled or denied.
Injection and infusion administration fees frequently underpaid or subject to site-of-care denials.
Lab work, imaging, and pathology related to oncology care with complex prior auth requirements.
Why Precision DX Group
Performance-based pricing. You pay nothing until we recover your revenue.
Automated denial prevention and appeal generation using ICD-10/NCCN guideline mapping.
Recover substantial historical denied claims from the past five years.
Success in wound care MA recovery now applied to oncology infusions.
Schedule a discovery call to see how much your practice could recover from denied oncology infusion claims.
Schedule a Discovery CallNo obligation. No upfront costs. 5-year lookback included.